Signed in as:
MRN Diagnostics provides a comprehensive toolbox of services and products to the in vitro diagnostics, biotechnology and pharmaceutical industries for the research, development and commercialization of diagnostic tests. We provide expertise and critical materials to support the discovery, development and launch of immunoassay, molecular genetic, anatomic pathology, chemistry and hematology-based laboratory tests.
Throughout the 1980s, access to well-pedigreed biospecimens was mostly limited to institutional collections and private archives. For researchers working in industry, prospective specimen collections were expensive and time consuming, but the only way to move biomedical research forward was to procure the needed specimens. To meet this need, Mr. McKie founded Bioclinical Partners in 1994 to provide a source of high quality biospecimens with accurate annotation, and a clear chain of custody. Bioclinical Partners was acquired by IMPATH in 1999.
Mr. Morin joined Bioclinical Partners in 2001, and later formed Bay State Biologicals to continue making high quality biospecimens available to industry researchers. In 2013 Mr. McKie and Mr. Morin formed Medical Research Networx to provide a broad array of services and products to enable research and development of laboratory testing in the life science industry.
In 2018 Dr. Gregory Chiklis joined the company as CEO/CSO and built a state of the art biorepository and a diagnostic research and manufacturing facility in Franklin, MA where the company now resides. This location will offer multiple products and services for Research, Development, Validation, Manufacturing and commercialization of diagnostic assays.
Chief Executive Officer
Chief Scientific Officer
Dr. Chiklis has developed and commercialized thousands of Diagnostic Research Products and Services over the last 30 years. These products are designed to cover all aspects of diagnostic development, validation, manufacturing, commercialization and quality control. Many of these products have been used to support regulatory submissions and to validate millions of test results globally. Dr. Chiklis graduated from the University of Massachusetts, Amherst in 1986, B.S. BioChemistry and in 1992 from University of Massachusetts Lowell with a Doctorate in Chemistry. His first job was at a start up Hemagen Diagnostics where he began his career developing assays. There he commercialized tests and quality control materials for the Research and IVD Marketplace. Next he moved to BioClinical Partners which eventually became ZeptoMetrix Corporation. There as Vice President of Research and Development and eventually CEO he developed and commercialized multiple products and services. Dr. Chiklis will use MRN's extensive and recently collected biospecimen archive and prospective collection capabilities to develop the most current and relevant research products on the market.
Chief Financial Officer
Chief Operating Officer
Mr. McKie began his career as a Sales Representative for North American Biologicals in 1986. Continuing his healthcare focus, in 1990 he became a Senior Sales Representative with Dianon Systems, Inc. He then moved on to Boston BioMedica, Inc. where from 1992 to 1994, he grew his responsibilities to become Director of Sales. In 1994, Mr. McKie co-founded BioClinical Partners, Inc. and served as Chief Operating Officer until 1999, when the business was acquired by IMPATH Inc. He was Vice President of Operations for the IMPATH Predictive Oncology™ division and was actively involved in the development and daily management of the Company's GeneBank™ initiative and the IMPATH Clinical Trials Network™ (ICTN). Following his work with IMPATH, Mr. McKie provided consulting services on behalf of hospitals and life science companies. He successfully developed clinical services worldwide, providing protocol-directed and IEC-approved clinical studies that continue to deliver thousands of biospecimens in oncology and infectious diseases annually. At Medical Research Networx, Mr. McKie provides strategic direction for the company with a vision to become the largest and most respected supplier of biospecimens and ancillary products and services to the diagnostics industry. Mr. McKie holds a BS degree in Business from Nova University.
MRN is experienced with all types of FDA submissions including 510(k), PMA, Humanitarian Use Devices and In Vitro Device Exemptions (IDEs). We have designed regulatory strategies for tests that span the full range of diagnostic technologies including immunoassay, cell-based assays and molecular diagnostic technologies. MRN has extensive experience with Laboratory Developed Testing strategies for high complexity CLIA-certified laboratories, and we have implemented compliant programs for Research Use Only and Investigational Use Only products, along with Analyte Specific Reagents.